Research Article
Comparison of Different Machine Learning Models in Prediction of Postirradiation Recurrence in Prostate Carcinoma Patients
Table 1
Comparison of patients’, disease, treatment, and follow-up characteristics between two groups of patients.
| | Characteristics | N (%) | Wilcoxon rank sum test | | Group 1 | Group 2 |
| | Age (years) | | | | | Mean (SD) | 70.9 (6.0) | 71.3 (5.8) | | | Median (range) | 71.0 (55.0-84.0) | 71.5 (60.0-80.0) | | T in clinical TNM | | | | | T1 | 1 (1.3%) | 0 (0%) | | | T2 | 70 (88.6%) | 16 (23.3%) | | T3 | 8 (10.1%) | 13 (43.3%) | | T4 | 0 (0%) | 1 (3.3%) | | N in clinical TNM | | | | | N0 | 75 (94.9%) | 29 (96.7) | | | N1 | 4 (5.1%) | 1 (3.3) | | UICC2 staging | | | | | I | 17 (21.5%) | 4 (13.3%) | | | II | 53 (67.1%) | 12 (40.0%) | | III | 6 (7.6%) | 13 (43.3%) | | IV | 3 (3.8%) | 1 (3.3%) | | Baseline PSA1 (ng/mL) | | | | | Mean (SD) | 48.0 (49.8) | 44.4 (57.3) | | | Median (range) | 30.1 (4.5-249.4) | 30.8 (7.0-311.0) | | Gleason’s score (category) | | | | | Low risk (GS3 6) | 8 (10.1%) | 6 (20.0%) | | | Intermediate risk (GS3 7) | 42 (53.2%) | 16 (53.3%) | | High risk (GS3 8-10) | 29 (36.7%) | 8 (26.7%) | | ADT4 | | | | | No | 23 (29.1%) | 12 (40.0%) | | | Yes | 56 (70.9%) | 18 (60.0%) | | ADT4 duration (months) | | | | | Mean (SD) | 12.4 (2.6) | 12.8 (1.4) | | | Median (range) | 12.0 (3.0-24.0) | 12.0 (12.0-15.0) | | Radiotherapy (Gy) | | | | | Mean (SD) | 66.6 (2.7) | 66.4 (2.4) | | | Median (range) | 65 (65-72) | 65 (65-72) | | Nadir PSA1 (ng/mL) | | | | Mean (SD) | 2.0 (5.6) | 4.0 (9.9) | | | Median (range) | 0.4 (0-42.9) | 0.6 (0-49.9) | | Time to nadir PSA1 (months) | | | | | Mean (SD) | 7.2 (5.5) | 5.9 (4.6) | | | Median (range) | 6.0 (1.0-31.0) | 4.0 (1.0-21.0) | | PSA1 doubling (months) | | | | | Mean (SD) | 6.9 (8.4) | 7.6 (9.9) | | | Median (range) | 3.9 (0.8-50.0) | 3.7 (0.9-42.0) | | PSA1 velocity (ng/mL/month) | | | | | Mean (SD) | 2.2 (4.2) | 2.4 (3.9) | | | Median (range) | 0.6 (0-26.1) | 1.0 (0-15.4) | | PSA1 in the moment of disease reevaluation | | | | | Mean (SD) | 23.1 (33.5) | 19.5 (24.8) | | | Median (range) | 12.3 (0.3-200.4) | 12.5 (0.04-120.0) | | Disease progression | | | | | No | 25 (31.6%) | 12 (40.0%) | | | Yes | 54 (68.4%) | 18 (60.0%) | | Site | | | | | Local recidive | 8 (10.1%) | 1 (3.3%) | | | Regional lymph nodes | 7 (8.9%) | 3 (10.0%) | | | Distant lymph nodes | 4 (5.1%) | 2 (6.7%) | | | Bone | 34 (43.0%) | 12 (40.0%) | | | Liver | 1 (1.3%) | 0 (0%) | | | Lung | 2 (2.5%) | 0 (0%) | | | Biochemical relapse | 11 (13.9%) | 4 (13.3%) | | | No. pts | 79 (100%) | 30 (100%) | |
|
|
1PSA = prostate-specific antigen; 2UICC = Union for International Cancer Control; 3GS = Gleason’s score; 4ADT = androgen deprivation therapy; Fisher exact test; #Pearson χ2 test. |
